

# Munich Cancer Registry



- Incidence and Mortality
- Selection Matrix
- Homepage
- *Deutsch*

## ICD-10 C69: Eye melanoma

### Survival

Year of diagnosis	1988-1997	1998-2020
Patients	101	512
Diseases	101	512
Cases evaluated	90	422
Creation date	04/15/2022	
Database export	12/20/2021	
Population	4.92 m	




Munich Cancer Registry  
Cancer Registry Bavaria - Upper Bavaria Regional Center  
at Klinikum Grosshadern/IBE  
Marchioninstr. 15  
Munich, 81377  
Germany

<https://www.tumorregister-muenchen.de/en>

[https://www.tumorregister-muenchen.de/en/facts/surv/sC69M\\_E-ICD-10-C69-Eye-melanoma-survival.pdf](https://www.tumorregister-muenchen.de/en/facts/surv/sC69M_E-ICD-10-C69-Eye-melanoma-survival.pdf)

## Index of figures and tables

Fig./Tbl.		Page
1a	Relative survival by period of diagnosis (chart)	3
1b	Survival by period of diagnosis (table)	3
2a	Survival by sex (chart)	4
2b	Survival by sex (table)	4
3a	Relative survival by age category (chart)	5
3b	Survival by age category (table)	5
4a	Relative survival by TNM staging (chart)	6
4b	Survival by TNM staging (table)	6
5a	Time to first progression (chart)	7
5b	Time to first progression (table)	7
5c	Observed post-progression survival (chart)	9
5d	Observed post-progression survival (table)	9
5e	Observed post-progression survival by period of progression (chart)	10
5f	Observed post-progression survival by period of progression (table)	10




**Figure 1a.** Relative survival of patients with eye melanoma by period of diagnosis. Included in the evaluation are 501 cases diagnosed between 1988 and 2020.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 2000 to 2018, and are represented by colored diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

Years	Period of diagnosis					
	1988-1997 n=90		1998-2006 n=155		2007+ n=256	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0
1	97.8	99.8	96.0	97.9	91.3	93.2
2	91.1	94.5	90.5	94.8	83.5	87.4
3	85.4	90.9	78.7	84.2	73.6	78.4
4	77.2	83.8	73.9	80.8	67.3	73.3
5	74.9	82.7	68.3	76.3	60.1	66.8
6	71.3	80.7	60.6	69.5	54.0	61.3
7	65.5	75.8	54.2	63.6	48.5	56.3
8	60.8	72.1	53.5	63.6	43.9	51.6
9	59.6	70.8	50.7	61.9	40.7	49.6
10	53.6	66.1	45.7	57.2	39.1	48.8
Median	10.8		9.1		6.6	


**Table 1b.** Observed (obs.) and relative (rel.) survival of patients with eye melanoma by period of diagnosis for period 1988-2020 (N=501).



**Figure 2a.** Survival of patients with eye melanoma by sex. Included in the evaluation are 411 cases diagnosed between 1998 and 2020.

Years	Sex			
	Male n=193		Female n=218	
	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	91.5	93.7	94.3	96.2
2	81.2	85.7	90.4	93.9
3	71.3	77.0	79.2	83.4
4	64.1	71.3	74.7	80.3
5	56.1	64.2	69.6	75.7
6	50.0	59.2	62.2	68.8
7	44.3	53.8	56.2	63.5
8	42.3	52.4	52.7	60.1
9	41.6	53.1	47.8	55.9
10	35.9	48.3	46.5	55.1
11	34.1	47.3	43.7	53.2
12	32.0	45.5	40.6	50.6
13	28.6	41.8	37.3	47.7
14	28.6	41.9	32.6	43.1
15			32.6	42.8
Median	6.0		8.4	


**Table 2b.** Observed (obs.) and relative (rel.) survival of patients with eye melanoma by sex for period 1998-2020 (N=411).



**Figure 3a.** Relative survival of patients with eye melanoma by age category. Included in the evaluation are 411 cases diagnosed between 1998 and 2020.

Years	Age category					
	0-54 yrs n=110		55-69 yrs n=145		70+ yrs n=156	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0
1	98.1	97.5	95.8	96.2	86.8	91.1
2	94.2	94.0	91.4	93.1	75.5	83.9
3	85.4	85.5	81.1	83.0	63.5	73.9
4	82.5	82.4	74.4	77.4	56.7	70.2
5	75.4	75.9	68.9	72.5	49.5	64.5
6	71.4	71.5	63.1	67.0	39.7	55.8
7	61.9	63.0	57.2	61.9	36.6	54.0
8	57.3	57.4	54.5	59.6	35.0	55.1
9	53.6	55.0	53.5	59.3	30.9	53.1
10	53.6	54.3	50.4	57.6	25.9	48.0
Median	12.7		10.9		4.9	


**Table 3b.** Observed (obs.) and relative (rel.) survival of patients with eye melanoma by age category for period 1998-2020 (N=411).



**Figure 4a.** Relative survival of patients with eye melanoma by TNM staging. For 197 of 411 cases diagnosed between 1998 and 2020 valid data could be obtained for this item. The accumulated percentage exceeds the 100 % value because patients are potentially considered in more than one subgroup. The grey line represents the subgroup of 214 patients with missing values regarding TNM staging (52.1 % of 411 patients, the percent values of all other categories are related to n=197).

TNM staging											
Years	T1+2 n=111		T3+4 n=60		M0 n=51		M1 n=26		NA/NOS n=214		
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	
1	97.3	98.9	94.8	97.8	98.0	98.8			95.1	97.0	
2	93.6	96.7	82.5	88.2	86.0	89.3			88.6	92.6	
3	89.0	93.1	64.9	70.2	74.0	78.0			78.5	83.7	
4	86.2	92.5	54.0	60.8	64.0	68.8			72.3	78.5	
5	80.2	87.1	52.2	60.3	59.6	63.7			63.6	70.8	
Median			5.3		6.0				6.5		

**Table 4b.** Observed (obs.) and relative (rel.) survival of patients with eye melanoma by TNM staging for period 1998-2020 (N=197).




**Figure 5a.** Time to first progression of 407 patients with eye melanoma diagnosed between 1998 and 2020 (in solid cancers M0 only) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

	Type of progression						
	Any type (CI)	Any type (1-KM)	Distant metastasis (CI)	Distant metast. (1-KM)	Locoreg. relapse (CI)	Locoreg. rel. (1-KM)	NOS (CI)
N	380	380	382	382	407	407	405
Events	258	258	157	157	42	42	140
compet.	40		54		187		168
Years	%	%	%	%	%	%	%
0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
1	33.9	34.0	4.5	4.6	1.7	1.8	27.5
2	44.9	45.3	14.0	14.4	4.3	4.6	31.1
3	54.0	54.8	23.1	23.9	6.6	7.4	31.9
4	58.7	59.8	28.6	29.7	7.7	8.8	32.4
5	63.7	65.2	34.6	36.2	9.0	10.8	33.2
6	65.6	67.5	38.1	40.2	9.6	11.7	34.0
7	66.8	68.9	40.5	43.0	10.2	12.8	34.0
8	67.6	70.0	42.8	45.8	10.5	13.4	34.0
9	68.8	71.6	43.4	46.6	11.1	14.7	34.6
10	70.4	73.7	44.2	47.6	11.1	14.7	35.5

Type of progression	
<i>cont'd</i>	NOS (1-KM)
N	405
Events	140
compet.	
Years	%
0	0.0
1	28.1
2	32.1
3	33.1
4	33.8
5	35.1
6	36.6
7	36.6
8	36.6
9	38.1
10	40.5

**Table 5b.** Time to first progression of patients with eye melanoma for period 1998-2020 (N=407), also showing the total of progression events (Events) and of deaths as competing risk (compet.).






**Figure 5c.** Observed post-progression survival of 272 patients with eye melanoma diagnosed between 1998 and 2020. These 272 patients with documented progression events during their course of disease represent 66.8 % of the totally 407 evaluated cases (incl. M1, n=27, 6.6 %). Patients with cancer relapse documented via death certificates only were excluded (n=22, 5.4 %). Multiple progression types on different sites are included in the evaluation even when not occurring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement “not specified” is the only information in registries regarding relapse of the disease. The category “Any type” denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100 % value because patients are potentially considered in more than one subgroup.

Years	Type of progression			
	Any type n=272 %	Distant metastasis n=163 %	Locoregional relapse n=44 %	NOS n=141 %
0	100.0	100.0	100.0	100.0
1	72.7	43.4	83.7	97.1
2	62.1	25.1	67.1	92.1
3	55.1	17.5		87.6
4	51.4			83.6
5	47.3			78.1
6	42.6			74.1
7	38.7			68.6
8	36.9			65.1
9	36.2			63.7
10	36.2			63.7

**Table 5d.** Observed post-progression survival of patients with eye melanoma for period 1998-2020 (N=272).



**Figure 5e.** Observed post-progression (distant metastasis) survival of 188 patients with eye melanoma diagnosed between 1988 and 2020 by period of progression.

Years	Period of progression	
	1998-2006 n=37 %	2007+ n=142 %
0	100.0	100.0
1		42.8
2		26.1
3		19.7

**Table 5f.** Observed post-progression (distant metastasis) survival of patients with eye melanoma for period 1988-2020 by period of progression (N=188).

## Shortcuts

MCR Munich Cancer Registry, Germany

NCI National Cancer Institute, USA

SEER Surveillance, Epidemiology, and End Results, USA

UICC Union for International Cancer Control, Geneva

DCO Death certificate only Death certificate provides the only notification to the registry.

NA Not available

NOS Not otherwise specified

OS Overall/Observed survival Overall/Observed survival (Kaplan-Meier estimate)

Date of entry: diagnosis  
Event: death from any cause

RS Relative survival Survival compared to “general population”, ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival

AS Assembled survival Assembled chart of observed, expected, relative survival

CS Conditional survival Survival probability under the condition of surviving a given period of time

TTP Time to progression Time to first progression / relapse  
Date of entry: diagnosis  
Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression

1-KM 1 minus Kaplan-Meier estimator (“inverse” Kaplan-Meier estimator)

CI Cumulative incidence  
Death as competing risk (according to Kalbfleisch und Prentice)

PPS Post-progression survival Survival since first progression / relapse (Kaplan-Meier estimate)  
Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression  
Event: death from any cause

## Recommended Citation

Munich Cancer Registry. Survival ICD-10 C69: Eye melanoma [Internet]. 2022 [updated 2022 Apr 15; cited 2022 Jun 1]. Available from: [https://www.tumorregister-muenchen.de/en/facts/surv/sC69M\\_E-ICD-10-C69-Eye-melanoma-survival.pdf](https://www.tumorregister-muenchen.de/en/facts/surv/sC69M_E-ICD-10-C69-Eye-melanoma-survival.pdf)

## Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

## Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.